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Abstract
Background: Drug discovery for the neglected tropical disease schistosomiasis has a high priority. Anticancer
drugs, especially protein kinase inhibitors, might serve as a starting point for drug discovery owing to the
importance of protein kinases in helminth growth and development. Furthermore, the Schistosoma mansoni
genome encodes several genes for targets of drugs marketed for human use, including several anticancer drugs.
Methods: In this study, we screened the approved oncology drug set of the National Cancer Institute’s
Developmental Therapeutic Program for antischistosomal activity. Drugs were tested in vitro against the larval and
adult stage of S. mansoni. IC50 values and albumin binding were determined for active compounds. Lead
compounds were tested in the chronic S. mansoni mouse model.
Results: Eleven of the 114 compounds tested revealed IC50 values ≤ 10 μM against both S. mansoni stages. Five of
these lost activity against adult S. mansoni in the presence of serum albumin. Of 6 compounds studied in vivo, the
highest activity was observed from two kinase inhibitors trametinib, and vandetanib, which reduced worm burden
by 63.6 and 48.1 % respectively, after a single oral dose of 400 mg/kg body weight.
Conclusion: Our study has confirmed that oncology drugs possess antischistosomal activity. There is space for
further investigation, including elucidation of the mechanisms of action of schistosome-active cancer drugs,
application of different treatment courses, and structure-activity relationship studies for improving drug potency.
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Background
Schistosomiasis is a neglected tropical disease caused by
the blood-dwelling fluke of the genus Schistosoma. The
clinically relevant species are S. mansoni, S. haematobium,
and S. japonicum. Approximately 779 million people live at
risk of infection, and 230 million are infected [1], causing
an estimated 3.3 million disability-adjusted life years
(DALYs) [2]. Praziquantel is the sole treatment against all
three species. The lack of drugs in the discovery pipeline
highly encourages efforts to identify an alternative treat-
ment of schistosomiasis, in anticipation of praziquantel re-
sistance [3, 4]. Drug repurposing is an efficient tool to find
new drugs against helminthiases, reducing time and costs
of drug research and development [5].
In recent years, imatinib (Gleevec®), a kinase inhibitor
used to treat chronic myeloid leukemia, gained attention in
the field of antischistosomal drug research due to its dose-
and time-dependent effect on S. mansoni in vitro [6]. It has
been observed that imatinib causes degenerative changes
in the gonads and gastrodermis of schistosomes [7]. Fur-
thermore, protein kinase inhibitors interfere with essential
developmental steps in the biology of schistosomes [6, 8].
We have recently identified N,N’-diarylureas as a new
chemical class potent against S. mansoni [9]. A subse-
quent structure-activity relationship (SAR) study revealed
N,N’-diarylureas and N-phenyl benzamides as the relevant
pharmacophores for antischistosomal drug activity [10].
These pharmacophores are also present in some marketed
anticancer drugs, such as sorafenib and ponatinib.
The Developmental Therapeutics Program (DTP) of
the National Cancer Institute (NCI) (USA) offers drug
repositories free of charge to endorse preclinical re-
search (https://dtp.nci.nih.gov/repositories.html); among
which is a set of the US Food and Drug Administration
(FDA)-approved anticancer drugs.
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There are 54 drugs for human use on the market which
exert their pharmacological effect on 26 drug targets which
are also encoded by the genome of S. mansoni [11]. Four-
teen of those drugs are part of DTP’s oncology drug set.
The aim of this study was to evaluate DTP’s oncology
drug set of 114 FDA-approved drugs for antischistosomal
activity. We tested the drugs first on the larval stage of S.
mansoni (schistosomula), followed by screening of larvae-
active compounds against adult worms. IC50 values were
then determined against adult S. mansoni, and the influ-
ence of protein binding on drug activity was assessed
using physiological amounts of serum albumin. The most
active compounds were subsequently tested in S. man-
soni-infected mice.
Methods
Drugs and media
The cancer drug library used for schistosome in vitro assays
was gratefully received in June 2014 from the DTP/NCI as
10 mM stock solutions (20 μl) in dimethyl sulfoxide
(DMSO) in 96-well plates. Hit compounds were or-
dered as solid compounds from DTP, and dissolved in
DMSO to 10 mM stock solutions. Bosutinib was not
available from DTP and was therefore purchased from
Sigma-Aldrich. For in vivo studies, solid afatinib, bosuti-
nib, ponatinib, trametinib, and vandetanib were purchased
from AkScientific. Sunitinib was purchased from VWR as
a 100 mM solution in DMSO.
Medium 199, and RPMI 1640 were purchased from
Life Technologies. Heat-inactivated fetal calf serum
(FCS), penicillin, and streptomycin were purchased from
LuBioScience.
Mouse infection and maintenance
Rodent experiments were authorized by the Canton
Basel-Stadt, Switzerland (license no. 2070).
Female NMRI mice, 3-weeks of age, were purchased
from Charles Rivers, Germany. After a 1-week adaptation
period, mice were infected with cercariae collected from S.
mansoni-infected intermediate host snails (Biompha-
laria glabrata), by subcutaneous injection with 100 cer-
cariae [12]. Mice received rodent food and water ad
libitum and were maintained with a 12-h light/dark cycle,
at 22 °C and 50 % humidity.
Larval schistosome drug assay
S. mansoni cercariae were collected from S. mansoni-in-
fected B.glabrata, and mechanically transformed to newly
transformed schistosomula (NTS) [13]. After a resting
period of 12–24 h (37 °C, 5 % CO2), drugs were tested for
NTS activity at a concentration of 33.3 μM in Medium
199 supplemented with 5 % FCS, 200 U/ml penicillin, and
200 μg/ml streptomycin, and prepared in 96-well flat-
bottom plates with 100 NTS per well. NTS incubated with
the equivalent volume of drug-free DMSO (0.3 %)
served as control. NTS were evaluated 24, 48, and
72 h after incubation via microscopic read out (80–120×
magnification; Zeiss; Germany), using a scoring scale from
3 (normal viability, morphology, and granularity) to 0 (no
motility, changed morphology, and granularity). Drugs with
an activity of ≥ 50 % after 24 h, and/or 90 % after 72 h, and
a drug effect on adult schistosomes of ≥ 80 % after 24 h
and/or 90 % after 72 h at 33.3 μM, were tested at six differ-
ent concentrations ranging from 0.14 to 33.3 μM using a 3-
fold dilution series for IC50 determination. All assays were
performed in duplicate and repeated once [10].
Adult schistosome drug assay
Adult schistosomes were collected from mice with a
chronic S. mansoni infection (7-week-old) by dissection of
the mesenteric veins. Drugs were tested at 33.3 μM in
RPMI 1640 culture medium supplemented with 5 % FCS,
100 U/ml penicillin, and 100 μg/ml streptomycin, and pre-
pared in 24-well flat-bottom plates. Three flukes of both
sexes were put into the wells, incubated at 37 °C, and 5 %
CO2, and scored (in the same manner as described for
NTS) after 1, 24, 48, and 72 h. Drugs revealing activity
against NTS, and adult schistosomes (as explained above),
were assessed for their IC50, using 3-fold serial dilutions
resulting in five different concentrations ranging from
0.41 to 33.3 μM, and scored 4, 24, 48, and 72 h post incu-
bation. IC50 determinations were performed in duplicate,
and repeated once [12]. For compounds exhibiting an
IC50 < 33.3 μM, IC50s were determined using culture
medium supplemented with 45 g/l bovine serum albumin
(AlbuMax® II Lipid-Rich BSA, Gibco): the physiological al-
bumin concentration in humans [14].
Preclinical and clinical data from FDA and EMA
FDA and European Medicines Agency (EMA) data sheets
were used to retrieve drug information such as the maximal
plasma concentration (Cmax), plasma half-life (t1/2), non-
clinical toxicology (lethal single oral dose LD50), indication,
mechanism of action, and dosage.
In vivo adult schistosome drug assay
For oral application, the drugs were dissolved in 7 % Tween
80 and 3 % ethanol in water (v/v/v), with the exception of
sunitinib, which was used as obtained. Groups of 4 mice
harboring a chronic S. mansoni infection were treated with
a single oral dose of 400 mg/kg body weight, or 200 mg/kg
for afatinib due to its low LD50 (382–763 mg/kg in mice)
[15]. A control group of 8 mice was left untreated. Three
weeks post treatment, the mice were euthanized, and schis-
tosomes residing in the mesenteric veins and the liver were
counted and sexed.
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Statistics
Drug effects on schistosomes were determined with the
scores of parasites exposed to drug, and the score of the
controls. For IC50 and r value (linear correlation coefficient)
determination, the dose-response was calculated with Com-
puSyn (version 3.0.1; ComboSyn), as described previously
[10]. In vivo worm burden reductions (WBR) were calcu-
lated with the number of worms found in treated mouse
groups compared to the control group [10]. P-values were
calculated using the Kruskal-Wallis test (Stats direct statis-
tical software version 2.8.0).
Results
In vitro studies
In vitro activities against NTS
DTP’s oncology drug set was first tested at 33.3 μM
against NTS (Fig. 1). Twenty-four drugs showed an ef-
fect ≥ 50 % after 24 h, and/or ≥ 90 % after 72 h. The
most active drugs were crizotinib, ponatinib, and tam-
oxifen citrate, killing NTS in less than 1 h. Afatinib, idar-
ubicin hydrochloride, regorafenib, sorafenib, and
temsirolimus were lethal to NTS within 24 h, everolimus
and sirolimus within 48 h, and bosutinib, daunorubicin,
and vandetanib within 72 h (Table 1).
Table 1 IC50 values of anticancer drugs against larval (NTS) and
adult stages of S. mansoni
Compound NTS: IC50
value [μM]
Adult S.
mansoni:
IC50
value
[μM]
Adult S. mansoni: IC50
value in the presence
of albumin [μM]
Regorafenib 6.9 1.0 >> 33.3
Ponatinib 0.2 1.1 20.2
Sorafenib 4.1 1.1 >> 33.3
Bosutinib 0.8 1.5 14.8
Afatinib 0.8 1.8 9.9
Sunitinib 1.0 1.8 10.6
Crizotinib 0.3 2.3 18.8
Trametinib 4.6 4.1 21.0
Tamoxifen citrate 2.0 5.7 >> 33.3
Gefitinib 7.8 8.3 >> 33.3
Cabozantinib 19.3 9.0 >> 33.3
Celecoxib 41.9 9.4 >> 33.3
Vandetanib 0.9 9.5 >> 33.3
Idarubicin HCl 12.7 16.2 >> 33.3
Mechlorethamine HCl > > 33.3 84.8 Not done
Fig. 1 Experimental flow
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In vitro activities against adult S. mansoni
The 24 NTS-active compounds were subsequently tested
on adult S. mansoni at 33.3 μM. Tamoxifen citrate was
the most active compound, killing all adult worms
within 1 h. Afatinib, ponatinib, and sorafenib caused
death of all adults within 24 h, whereas adult worms in-
cubated with bosutinib and idarubicin hydrochloride
were dead after 72 h. In total, 15 compounds were clas-
sified as active against adult S. mansoni, characterized by
an effect ≥ 80 % after 24 h, and/or ≥ 90 % after
72 h (Table 1).
Determination of IC50 values
These 15 compounds were investigated further by asses-
sing their IC50 values against adult worms and NTS.
Eleven compounds (structures depicted in Table 2) re-
vealed high activities (IC50 ≤ 10 μM) against both stages
after 72 h.
However, IC50 values increased in the presence of albu-
min. In medium supplemented with 45 g/L BSA, only 6
compounds showed activity (IC50 of 9–21 μM against
adult S. mansoni), namely afatinib, bosutinib, crizotinib,
ponatinib, suntinib, and trametinib. For the remaining
compounds tested, no IC50 could be calculated due to lack
of activity.
Preclinical and clinical data
Data on pharmacokinetic parameters, toxicity, and other
information of interest accessible from the FDA and the
EMA (summarized in Table 3) were consulted for the 11
Table 2 Chemical structures of lead compounds
afatinib bosutinib crizotinib
gefitinib ponatinib regorafenib
sorafenib sunitinib tamoxifen
trametinib vandetanib
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Table 3 FDA and EMA drug description of anticancer drugs of lead compounds
Drug Cmax Single oral dose (or otherwise as
indicated)
t1/2 Single oral dose (or
otherwise as indicated)
LD50 Single oral
dose toxicity
Indication Mechanism
of action
Dosage Reference
(health
agency)
Afatinib
(GIOTRIF®)
NA 37 h (after repeated dosing given
to patients)
NA Metastatic non-small
cell lung cancer
Irreversible inhibitor
of tyrosine kinase
autophos-phorylation
40 mg/day FDA
397 nmol/l (1×8 mg/kg
given to rats)
4.5 h (1×8 mg/kg given to rats) 382–763 mg/kg
(mice)
EMA
Bosutinib
(BOSULIF®)
0.2 μg/ml (500 mg given to
patients on 15 consecutive days)
22 h (patients; dose not
indicated)
NA Chronic, accelerated,
or blast phase Ph + chronic
myelogenous leukemia
Tyrosine kinase
inhibitor
500 mg/day FDA
NA 2.5–5.4 h (mice and rats; dose
not indicated)
>2000 mg/kg
(mice and rats)
EMA
Crizotinib
(XALKORI®)
100–135 ng/ml (250 mg
given to patients)
42 h (250 mg given to patients) >500 mg/kg (rats) Metastatic non-small
cell lung cancer
Tyrosine kinase
inhibitor
2×250 mg/day FDA
NA 5.8–13 h (rats; dose not
indicated)
NA EMA
Gefitinib
(IRESSA®)
NA 48 h (healthy volunteers; dose
not indicated)
NA Non-small cell lung cancer Multiple tyrosine kinase
inhibitor
250 mg/day FDA
1 μg/ml (after 20 mg/kg given
to rats); 0.1 μg/ml (after 250 mg/kg
given to healthy volunteers)
10 h (rats; dose not indicated);
30 h (after 250 mg/kg given to
healthy volunteers)
Around 2000
mg/kg (rats); >
1000 mg/kg (dogs)
EMA
Ponatinib
(INCLUSIG®)
6 h (patients; dose
not indicated)
24 h (patients; dose not
indicated)
>2000 mg/kg
(mice)
Chronic myeloid leukemia Tyrosine kinase
inhibitor
45 mg/day FDA
4 h (patients; dose
not indicated)
22 h (patients; dose not
indicated)
NA EMA
Regorafenib
(STIVAGRA®)
12.5 μg/ml (after 160 mg
given to patients)
24 h (after 160 mg
given to patients)
NA Metastatic colon cancer Multiple protein kinase
inhibitor
160 mg/day for
first 21 days of a
28-day cycle
FDA
3.96 mg/l (multiple treatment: 160
mg/day for 3 weeks given to patients)
2 h (multiple treatment; 160
mg/day for 3 weeks given
to patients)
>250 mg/kg
(mice and rats)
EMA
Sorafenib
(NEXAVAR®)
NA 25–48 h NA Liver, kidney, thyroid cancer Multiple protein kinase
inhibitor
2×400 mg/day FDA
0.55 mg/l (after 400 mg given
to patients)
22.3 h (after 400 mg given to
patients)
>1460 mg/kg
(mice and rats)
EMA
Sunitinib
(SUTENT®)
NA 40–60 h (parent drug in healthy
volunteers; 80–110 h (active
metabolite in healthy volunteers
(dose not indicated)
NA Gastrointestinal stromal
tumor, renal cell carcinoma,
well-differentiated pancreatic
neuroendocrine tumors
Inhibitor of multiple
receptor tyrosine
kinases
50 mg/d for the
first 28 days of a
42-day cycle
FDA
NA NA >500 mg/kg
(mice and rats)
EMA
Trametinib
(MEKINIST®)
NA Estimated: 3.9–4.8 days
(patients; dose not indicated)
NA Kinase inhibitor 2 mg/day FDA
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Table 3 FDA and EMA drug description of anticancer drugs of lead compounds (Continued)
Unresectable or metastatic
melanoma with BRAF V600E
or V600K mutations
22.2 ng/ml (steady state after 2
mg/daygiven to healthy volunteers)
5.3 days (healthy volunteers;
dose not indicated)
NA EMA
Tamoxifen citrate
(NOLVADEX®)
40 ng/ml (after 20 mg given to rats) 5–6 days (after 20 mg
given to rats)
NA Breast cancer Nonsteroidal
antiestrogen
NA FDA
NA NA NA 20 mg/day EMA
Vandetanib
(CAPRELSA®)
NA NA NA Medullary thyroid cancer Multiple tyrosine kinase
inhibitor
300 mg/day FDA
NA 19 days (after 300 mg given to
healthy volunteers)
NA EMA
NA Not available on the data sheets of the according health agency
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compounds characterized by an IC50 ≤ 10 μM against both
stages in order to select good in vivo candidates. With
regards to potential drug exposure time, vandetanib has a
very long half-life (19 days in humans), which we consid-
ered an advantageous feature for killing parasites that res-
ide in the bloodstream.
Activity in S. mansoni-infected mice
Afatinib, bosutinib, ponatinib, sunitinib, trametinib, and van-
detanib were chosen for in vivo studies based on their in
vitro activity against schistosomes, and review of the litera-
ture. Of note, since crizotinib was not affordable, it was not
tested in vivo. Drugs were orally applied to mice in a single
dose of 400 mg/kg body weight; except for afatinib, which
was administered at a single dose of 200 mg/kg, given its
lower LD50. Trametinib, and vandetanib had the highest
WBRs of 63.6 %, and 48.1 % respectively (p-value > 0.05).
The remaining compounds were only marginally, or not at
all efficacious, with WBRs between 0–27.5 % (Table 4).
Discussion
New drugs are needed to treat the neglected tropical dis-
ease schistosomiasis. In the present work, we applied a re-
purposing strategy using a set of FDA-approved anticancer
drugs. This library was chosen given proposed overlaps in
mechanism of action, active pharmacophores, and matches
of human drug targets found in the genome of S. mansoni
[6, 11, 16].
Because repurposing builds upon previous research and
development efforts, new antischistosomal drugs could
quickly advance into clinical testing, greatly diminishing
the huge costs of drug development [5]. However, it is
worth reflecting on the selected library. Anticancer agents
are often characterized by the occurrence of numerous and
severe adverse events. Since anthelmintic chemotherapy
consists typically of a single dose [17], the adverse events
occurring during the intensive multiple-dose regimens of
cancer chemotherapy [18], would probably not occur. This
encourages studying the anthelmintic properties of anti-
cancer drugs further and in more detail. However, the
health-risk benefits of repurposing cancer drugs should be
evaluated on a case-by-case basis.
We identified 11 cancer drugs in this work with high in
vitro activity against adult and larval S. mansoni. It is
worth highlighting that 10 of these drugs are protein kin-
ase inhibitors, which have been suggested as potentially
interesting antischistosomal drug discovery candidates,
since protein kinase inhibitors can interfere with signaling
pathways in schistosome development [6]. The exact
mechanism(s) of action of these drugs on schistosomes re-
main yet to be elucidated, although apoptosis might be in-
volved, due to the fact that many protein kinase inhibitors
induce apoptosis [19].
Six of these compounds maintained their antischis-
tosomal activity when exposed to serum albumin - the
predominant plasma protein in humans [14] - while
the antischistosomal activity of 5 lead candidates was
strongly negatively influenced by serum albumin. The
loss of in vitro antischistosomal activity of imatinib (a pro-
tein kinase inhibitor, which did not progress further in our
screens) in the presence of alpha-1-acid glycoprotein,
serum albumin, and especially with a combination of both,
has been described recently [20]. The influence of alpha-1-
acid glycoprotein on the in vitro activity of our lead com-
pounds was not studied in the present work since binding
to this protein might play a more crucial role in rodents
than in humans, as described below.
In vivo drug efficacy determination, based on our in vitro
findings (taking into account the loss of activity in the pres-
ence of albumin), as well as a literature review on preclin-
ical and clinical data of these drugs (Table 3), revealed two
kinase inhibitors: trametinib, and vandetanib, with moder-
ate WBRs of 63.6 and 48.1 % respectively. Vandetanib’s effi-
cacy was somewhat surprising, since the addition of
albumin to the in vitro IC50 determination led to inactivity
of the drug. Protein binding to serum albumin, and apha-1-
acid glycoprotein (90 %) was also highlighted by the
manufacturer [21]. However, trametinib and vandeta-
nib have a high bioavailability of 100 % [22], or > 90 %
[23] in rodents. Additionally, both drugs have long half-
lives: 3 days in rats and mice for trametinib [24]; and 28 h
in mice for vandetanib [25]. In humans, both trametinib
and vandetanib also have exceptionally long half-lives:
4.2 days (3.9 – 4.5 days) [26], and 19 days [27] respectively.
The high bioavailabilities combined with the long half-lives
might therefore outweigh the negative influence of protein
binding on the antischistosomal activity, and explain the ef-
ficacy against S. mansoni in the mouse model. There might
even be a possibility for higher efficacy of vandetanib in
humans, since the alpha-1-acid glycoprotein homeostasis is
species-dependent. While this serum protein in humans
Table 4 In vivo worm burden reductions after a single oral dose
of 200 mg/kg (afatinib) or 400 mg/kg body weight (remaining
drugs) to mice harboring a chronic S.mansoni infection
Drug Number of mice treated Average worm
count (SD)
WBR [%]
Control1 8 20.4 (12.4) -
Control2 8 23.0 (18.4) -
Trametinib1,2 5 8.1 (4.1) 63.6
Vandetanib1,2 5 11.3 (8.4) 48.1
Afatinib1 4 14.8 (11.1) 27.5
Ponatinib1 3 16.6 (12.9) 18.6
Sunitinib1 4 22.5 (8.5) 2.2
Bosutinib1 4 25.3 (4.0) 0
P value of all WBRs was > 0.05; Values in superscript refer to the
corresponding control group
SD standard deviation
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increases 2–5-fold upon inflammatory processes, the in-
crease in mice is 30–40-fold, which is a crucial difference
when alpha1-acid glycoprotein-sensitive drugs are being
evaluated [16].
Interestingly, none of the 14 drugs, for which the genes
of the corresponding human drug targets also exists in S.
mansoni [11], revealed noteworthy antischistosomal activ-
ity (IC50 > 33.3 μM) (data not shown). Only temsirolimus,
and sirolimus killed NTS within 24 or 48 h respectively;
but neither of the two reduced the viability of adult S.
mansoni considerably. However, we would like to high-
light that our drug activity assessments are based on alter-
ations on the parasite phenotype. We did not determine
the effect on schistosome development, such as the repro-
ductive organs, or egg production and expulsion, which
might be affected by the 14 drugs.
When comparing our in vitro results with those of other
research groups, differences in drug activity are notable.
Under our screening conditions, at 33.3 μM, and 72 h
drug exposure, imatinib showed <70 % activity against
schistosomula, and 76 % against adult schistosomes, while
all worms were still moving. In contrast, Beckmann and
Grevelding (2010) described the activity of imatinib (72 h
postincubation) to be fatal for 30 % of all adult worms
after incubation at 10 μM, or 63 % after incubation at
50 μM [6]. According to Katz et al (2013), 6 % of worms
died after incubation with imatinib (25 μM for 24 h),
followed by 48 h in drug-free culture medium [28]. The
reason for the different survival rate is not clear, but might
originate from differences in drug susceptibilities of differ-
ent S. mansoni strains (Puerto Rican; Luiz Evangelista ver-
sus Liberian).
Conclusion
In summary, the oncology drug set revealed several in vitro-
active drugs against S. mansoni; of which two (trametinib,
and vandetanib) were also moderately active in vivo. There
is room to further investigate trametinib’s and vandetanib’s
potential as antischistosomal drugs, including elucidation of
mechanisms of action, application of different treatment
courses, and structure-activity relationship studies.
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